Mae pathophysiology canser y fron yn cyfeirio at y newidiadau annormal yn y prosesau a'r mecanweithiau ffisiolegol arferol sy'n digwydd wrth ddatblygu a datblygu canser y fron.
Mae'n cynnwys astudiaeth o'r mecanweithiau biolegol a moleciwlaidd sylfaenol sy'n arwain at dwf a lledaeniad di-reolaethol celloedd canser yn y meinwe fron.
Mae hyn yn cynnwys y ffactorau genetig, epigenetig, ac amgylcheddol sy'n cyfrannu at gychwyn, hyrwyddo, a datblygu canser y fron.
Mae rhai o'r newidiadau pathophysiolegol allweddol mewn canser y fron yn cynnwys:
1. Mutasau genetig: Gall mutasau mewn rhai gennau, fel BRCA1 a BRCA2, gynyddu'r risg o ddatblygu canser y fron.
Gall y mudiadau hyn gael eu etifeddu neu eu caffael yn ystod oes person.
2. Anghydbwysedd hormonau: Gall hormonau, yn enwedig estrogen, chwarae rhan mewn datblygiad a thwf canser y fron.
Gall anghydbwysedd mewn lefelau hormonau neu amlygiad i ormod o estrogen gynyddu'r risg o ganser y fron.
3. llid: Gall llid cronig yn y meinwe'r fron gyfrannu at ddatblygiad canser y fron trwy hyrwyddo twf a goroesi celloedd canser.
4. Microamgylchedd y tiwmor: Gall yr amgylchedd sy'n amgylchynu'r tiwmor, gan gynnwys y matrix allanol, celloedd imiwnedd, a chwarel gwaed, ddylanwadu ar dwf a lledaeniad canser y fron.
5. Metastasis: Gall canser y fron ledaenu i rannau eraill o'r corff trwy'r system limffig neu'r ffrwd gwaed, gan arwain at ffurfio tumorau eilaidd mewn organau pell.
Mae deall pathophysiology canser y fron yn hanfodol ar gyfer datblygu strategaethau atal effeithiol, canfod cynnar, a thriniaeth.
Underwood SM: Breast cancer in African American women: nursing essentials. ABNF J. , 17 (1): 3-14.
Paliwal SR, Paliwal R, Agrawal GP, Vyas SP: Liposomal nanomedicine for breast cancer therapy. Nanomedicine (Lond). 2011, 6 (6): 1085-100.
Rauch GM, Adrada BE: Comparison of Breast MR Imaging with Molecular Breast Imaging in Breast Cancer Screening, Diagnosis, Staging, and Treatment Response Evaluation. Magn Reson Imaging Clin N Am. 2018, 26 (2): 273-280.
Wei H, Wang H, Ji Q, Sun J, Tao L, Zhou X: NRBP1 is downregulated in breast cancer and NRBP1 overexpression inhibits cancer cell proliferation through Wnt/β-catenin signaling pathway. Onco Targets Ther. 2015, 8 (): 3721-30.
Eden JA: Human breast cancer stem cells and sex hormones--a narrative review. Menopause. 2010, 17 (4): 801-10.
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA: Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008, 14 (24): 8010-8.
Gwaharddiad cyfrifoldeb: meddygol
Mae'r wefan hon yn cael ei ddarparu at ddibenion addysgol a gwybodaeth yn unig ac nid yw'n darparu cyngor meddygol neu wasanaethau proffesiynol.
Ni ddylid defnyddio'r wybodaeth a ddarperir i ddiagnosio neu drin broblem neu glefyd iechyd, a dylai'r rhai sy'n ceisio cyngor meddygol personol ymgynghori â meddyg trwyddedig.
Sylwch fod y rhwydwaith niwrol sy'n cynhyrchu atebion i'r cwestiynau, yn arbennig o anghywir pan ddaw i gynnwys rhifol. Er enghraifft, nifer y bobl sy'n cael diagnosis o glefyd penodol.
Ceisiwch gyngor eich meddyg neu ddarparwr iechyd cymwys arall bob amser ynghylch cyflwr meddygol. Peidiwch byth ag anwybyddu cyngor meddygol proffesiynol neu ohirio ei geisio oherwydd rhywbeth rydych chi wedi ei ddarllen ar y wefan hon. Os ydych chi'n meddwl y gallai fod gennych argyfwng meddygol, ffonwch 911 neu ewch i'r ystafell brys agosaf ar unwaith. Nid oes unrhyw berthynas meddyg-cleifion yn cael ei greu gan y wefan hon na'i ddefnydd. Nid yw BioMedLib na'i weithwyr, na unrhyw gyfrannwr i'r wefan hon, yn gwneud unrhyw gynrychiolaeth, yn glir neu'n awgrymol, mewn perthynas â'r wybodaeth a ddarperir yma na'i ddefnydd.
Gwrthod cyfrifoldeb: hawlfraint
Mae Deddf Hawlfraint y Mileniwm Digidol o 1998, 17 U.S.C. § 512 (y DMCA) yn darparu adnodd i berchnogion hawlfraint sy'n credu bod deunydd sy'n ymddangos ar y Rhyngrwyd yn torri eu hawliau o dan gyfraith hawlfraint yr Unol Daleithiau.
Os ydych chi'n credu mewn ffydd da bod unrhyw gynnwys neu ddeunydd a wnaed ar gael mewn cysylltiad â'n gwefan neu'n gwasanaethau yn torri eich hawlfraint, gallwch chi (neu'ch asiant) anfon hysbysiad atom yn gofyn i'r cynnwys neu'r ddeunydd gael ei ddileu, neu fod mynediad ato wedi'i rwystro.
Rhaid i rybuddion gael eu hanfon yn ysgrifenedig trwy e-bost (gweler adran "Cyflwyniad" am gyfeiriad e-bost).
Mae'r DMCA yn gofyn i'ch hysbysiad o dorri hawlfraint honedig gynnwys y wybodaeth ganlynol: (1) disgrifiad o'r gwaith hawlfraint sy'n destun y dorri hawlfraint honedig; (2) disgrifiad o'r cynnwys sy'n dorri hawlfraint honedig a gwybodaeth ddigonol i'n galluogi i ddod o hyd i'r cynnwys; (3) gwybodaeth gyswllt i chi, gan gynnwys eich cyfeiriad, rhif ffôn a chyfeiriad e-bost; (4) datganiad gan chi bod gennych gred ffyddlon nad yw'r cynnwys yn y ffordd sy'n cwyno amdano wedi'i awdurdodi gan berchennog yr hawlfraint, neu ei asiant, neu gan weithredu unrhyw gyfraith;
(5) datganiad gennych chi, wedi'i lofnodi o dan gosb llygredd, bod y wybodaeth yn y hysbysiad yn gywir ac bod gennych chi'r awdurdod i orfodi'r hawlfraint sy'n cael eu troseddu;
a (6) llofnod corfforol neu electronig o berchennog y hawlfraint neu berson wedi'i awdurdodi i weithredu ar ran perchennog y hawlfraint.
Gall methu â chynnwys yr holl wybodaeth uchod arwain at oedi wrth brosesu'ch cwyn.
Cysylltwch
Anfonwch e-bost i ni gyda unrhyw gwestiwn / awgrym.
What is pathophysiology of breast cancer?
Pathophysiology of breast cancer refers to the abnormal changes in the normal physiological processes and mechanisms that occur in the development and progression of breast cancer.
It involves the study of the underlying biological and molecular mechanisms that lead to the uncontrolled growth and spread of cancer cells in the breast tissue.
This includes the genetic, epigenetic, and environmental factors that contribute to the initiation, promotion, and progression of breast cancer.
Some of the key pathophysiological changes in breast cancer include:
1. Genetic mutations: Mutations in certain genes, such as BRCA1 and BRCA2, can increase the risk of developing breast cancer.
These mutations can be inherited or acquired during a person's lifetime.
2. Hormonal imbalances: Hormones, particularly estrogen, can play a role in the development and growth of breast cancer.
An imbalance in hormone levels or exposure to excess estrogen can increase the risk of breast cancer.
3. Inflammation: Chronic inflammation in the breast tissue can contribute to the development of breast cancer by promoting the growth and survival of cancer cells.
4. Tumor microenvironment: The environment surrounding the tumor, including the extracellular matrix, immune cells, and blood vessels, can influence the growth and spread of breast cancer.
5. Metastasis: Breast cancer can spread to other parts of the body through the lymphatic system or bloodstream, leading to the formation of secondary tumors in distant organs.
Understanding the pathophysiology of breast cancer is crucial for developing effective prevention, early detection, and treatment strategies.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Am tua
Mae BioMedLib yn defnyddio cyfrifiaduron awtomatig (algorithmau dysgu peiriant) i gynhyrchu pâr cwestiynau a atebion.
Rydym yn dechrau gyda 35 miliwn o gyhoeddiadau biofeddygol o PubMed/Medline. Hefyd, tudalennau gwe o RefinedWeb.
